Less Ads, More Data, More Tools Register for FREE

Pin to quick picksVERS.L Regulatory News (VERS)

  • There is currently no data for VERS

Additional Listing & Total Voting Rights

27 Oct 2016 08:41

RNS Number : 6150N
Verseon Corporation
27 October 2016
 

27 October 2016

 

Verseon Corporation

 

("Verseon" or the "Company")

 

Additional Listing & Total Voting Rights

 

Verseon, a technology-based pharmaceutical company, announces that on 25 October 2016, Mr. Grover Wickersham, Non-Executive Director of the Company, has been issued a grant of restricted stock units ("RSUs") that relate to payment of his Director's fees in the form of restricted stock. Mr. Wickersham's restricted stock grant totals 15,463 Common Shares and is calculated by reference to the closing price on 25 October 2016 of the Company's common shares in USD, being $1.94. The RSUs vest quarterly in equal proportions over a 6 month period starting from 30 October 2016.

 

For further information please contact:

 

Verseon Corporation

+1 (510) 225 9000

Arthur Shmurun / Amy Thai

Cenkos Securities (NOMAD and Broker)

+44 (0) 20 7397 8900

Mark Connelly / Steve Cox

Buchanan Communications Ltd (PR Advisers)

+44 (0) 20 7466 5000

Henry Harrison-Topham / Sophie Cowles

 

 

1

 

Details of the person discharging managerial responsibilities / person closely associated

 

a)

 

Name

 

 

Mr Grover Wickersham

2

 

Reason for the notification

 

a)

 

Position/status

 

 

Non-Executive Director

b)

 

Initial notification /Amendment

 

 

Initial notification

3

 

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

 

a)

 

Name

 

 

Verseon Corporation

b)

 

LEI

 

 

N/a

4

 

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted

 

 

a)

 

Description of the financial instrument, type of instrument

 

Identification code

 

 

Restricted stock grant of Common Shares of par value $0.001

 

ISIN: USU9221J1098

 

 

b)

 

Nature of the transaction

 

 

Issuance of restricted stock units

c)

 

Price(s) and volume(s)

 

 

 

Price(s)

 

Volume(s)

$1.94

15,463

 

 

d)

 

Aggregated information

 

- Aggregated volume

 

 

- Price

 

 

 

15,463

 

 

$1.94

e)

 

Date of the transaction

 

 

25 October 2016

f)

 

Place of the transaction

 

 

N/a

 

 

 

This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
MSCEAXEXADNKFEF
Date   Source Headline
24th Oct 20187:00 amRNSAnnouncement of 2018 Annual General Meeting
11th Oct 20187:00 amRNSBlockchain agreement with Neuseren
1st Oct 20188:59 amRNSAdditional Listing & Total Voting Rights
18th Sep 20187:00 amRNSVerseon unveils new blockchain technology
13th Sep 20187:00 amRNSVerseon commences anticoagulant phase I trial
31st Aug 20187:00 amRNSAdditional Listing & Total Voting Rights
16th Aug 20187:00 amRNSChange of Adviser
8th Aug 20187:00 amRNSInterim Results
18th Jul 20187:00 amRNSVerseon submits phase I protocol for VE-1902
6th Jul 20187:00 amRNSAdditional Listing & Total Voting Rights
2nd Jul 20187:00 amRNSAdditional Listing & Total Voting Rights
25th Jun 20187:00 amRNSFinal Results
14th Jun 20187:00 amRNSVerseon preparing for anticoagulant phase I trial
13th Jun 20187:03 amRNSVerseon closes US$ 22.7M mortgage
12th Jun 20187:00 amRNSAdditional Listing & Total Voting Rights
7th Jun 20187:00 amRNSVerseon presents anticoagulants at BIO 2018
2nd May 20187:00 amRNSVerseon presents DME efficacy data at ARVO 2018
18th Apr 20187:00 amRNSVerseon presents anticancer agents at AACR 2018
3rd Apr 20187:00 amRNSAdditional Listing & Total Voting Rights
5th Mar 20187:00 amRNSAdditional Listing & Total Voting Rights
10th Jan 20187:00 amRNSVerseon presents HAE program at Biotech Showcase
2nd Jan 20187:00 amRNSAdditional Listing & Total Voting Rights
15th Nov 20177:00 amRNSVerseon presents second anticoagulant candidate
14th Nov 20177:00 amRNSAdditional Listing & Total Voting Rights
8th Nov 20177:00 amRNSVerseon presents anticancer agents at BIO-Europe
8th Nov 20177:00 amRNSAdditional Listing & Total Voting Rights
20th Oct 20177:00 amRNSResult of Special Meeting & Board Appointment
2nd Oct 20177:00 amRNSVerseon presents new DME efficacy results
25th Sep 20177:00 amRNSInterim Results
25th Sep 20177:00 amRNSSpecial Shareholder Meeting & Change of Directors
22nd Sep 20177:00 amRNSVerseon closes PACE financing for its new facility
7th Aug 20177:00 amRNSAdditional Listing and Total Voting Rights
26th Jun 20177:00 amRNSVerseon presents data on DME program at BIO 2017
12th Jun 20177:00 amRNSVerseon to present drug programs at BIO 2017
6th Jun 20178:15 amRNSTransaction in Own Shares and Total Voting Rights
2nd May 20177:00 amRNSAdditional Listing & Total Voting Rights
26th Apr 20177:00 amRNSTR-1 Notification of Major Interest in Shares
26th Apr 20177:00 amRNSResult of 2017 Annual General Meeting
3rd Apr 20177:00 amRNSAnnouncement of 2017 Annual General Meeting
30th Mar 20177:00 amRNSVerseon to present anticoagulants at ACS 2017
20th Mar 20177:00 amRNSBIO-Europe Spring: Verseon presents anticoagulants
13th Mar 20177:00 amRNSFinal Results
30th Jan 20177:00 amRNSAdditional Listing & Total Voting Rights
4th Jan 20177:00 amRNSVerseon granted US patents for its inhibitors
6th Dec 20167:00 amRNSLower bleeding risk of Verseon anticoagulants
23rd Nov 20167:03 amRNSVerseon anticoagulants preserve platelet function
16th Nov 20167:00 amRNSAdditional Listing & Total Voting Rights
14th Nov 20167:00 amRNSNew anticoagulant data to be presented at AHA 2016
7th Nov 20167:00 amRNSAppointment of Corporate Brokers
31st Oct 20167:00 amRNSAdditional Listing & Total Voting Rights

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.